Showing posts with label virus. Show all posts
Showing posts with label virus. Show all posts

17 April 2009

Batteries from Viruses

Researchers have recently created rechargeable batteries consisting of genetically-engineered viruses which automatically coat themselves with a metallic layer. This was done by introducing DNA to the M13 virus, which usually infects bacteria, causing it to produce specific molecules on its surface which attract cobalt ions and gold. The result was the formation of an anode, or negative terminal of a battery. Next, a cathode, or the positive terminal, was produced by inserting another additional gene which caused the virus to attract iron and phosphate ions to its surface.

Lithium ion batteries work by passing lithium ions from the anode to the cathode inside the battery, and this drives electrons through the external circuit. Therefore, for a lithium ion battery to work effectively, it must be able to conduct both lithium ions and electrons. Researchers found that the virus which they currently had could conduct lithium ions well, but not electrons. To overcome this problem, they added yet another gene to the virus which caused it to produce a protein at its tip which would attach to a carbon nanotube (shown above). The network of carbon nanotubes coupled with the viruses worked effectively as an electron conductor.

The viral battery which was finally produced had a capacity and power performance which matched conventional lithium ion batteries available on the market. In addition to that, the process of manufacturing the battery from viruses could be conducted at room temperature using only water as a solvent. In contrast, the manufacture of conventional batteries requires the use of high temperatures and aggressive solvents. Yet another advantage of the virus-based battery is that it does not leave behind toxic chemicals when it degrades, making it a potential candidate for green batteries of the future. The battery could possibly be used in hybrid vehicles or in portable electronic equipment.

However, materials engineer Angela Belcher, one of the researchers behind this technology, cautions that the newly-designed battery is not yet commercially viable. Her team is currently looking into materials which produce greater voltages and have larger energy storage capacities.

Xiang Wen Lee
42027285


References:

Cahoon, L 2009, Bugs Build Batteries, viewed 16 April 2009, <http://sciencenow.sciencemag.org/cgi/content/full/2009/403/1>

Hutson, S 2006, Battery electrodes self-assembled by viruses, viewed 16 April 2009, <http://www.newscientist.com/article/dn8961-battery-electrodes-selfassembled-by-viruses.html>

Zandonella, C 2009, Batteries grown from 'armour-plated' viruses, viewed 16 April 2009, <http://www.newscientist.com/article/mg20227035.400-batteries-grown-from-armourplated-viruses.html>

21 March 2009

Human Genes Required For Hepatitis C Viral Replication Identified

Although a few years away from being a possible therapeutic strategy, researchers from Massachusetts General Hospital (MGH) have made a startling discovery in the way they can block the reproduction of the hepatitis C virus (HCV).

Initial research to harness the replication of the hepatitis C virus related to the actual virus itself, with any form of treatment having a low success rate and often serious side effects that are intolerable for the patient. The new study reveals they can successfully block & suppress reproduction of the virus in cultured cells by targeting the genes that the virus utilises during its life cycle.

“For the current study the researchers examined whether blocking each of the approximately 21,000 predicted messenger RNA transcripts in the human genome with small interfering RNAs (siRNAs) had any effect on HCV replication.”

The results showed that 96 genes are associated with viral replication, from which they focused on several to conclude that blocking each of the particular genes, (one that focused on the coding of an enzyme called PI4KA, one that contributed to the formation of the COPI coat & one responsible for the regulation of the hepcidin protein), also blocked the HCV replication. Similar results were found when drugs were used to restrain the enzyme PI4KA & COPI.

Such research is vital as hepatitis C infects close to 200 million people worldwide & long-term infection can often lead to liver failure & liver cancer.

Such study is being attempted for other viruses including influenza, West Nile virus & HIV; one can only hope such progress is made.

"Now we need to work to uncover the molecular mechanisms by which these genes support HCV replication to get a better idea of which would be advantageous therapeutic targets," explains Raymond Chung, MD, director of Hepatology in the MGH Gastrointestinal Unit, the study's senior author.

s4175707

1. http://www.medicalnewstoday.com/articles/142921.php

2. http://harvardscience.harvard.edu/sites/default/files/full/hepCfull.jpg (IMAGE)

3. http://upload.wikimedia.org/wikipedia/commons/thumb/9/90/HCV_prevalence_1999.png/800px-HCV_prevalence_1999.png (image)

4. http://en.wikipedia.org/wiki/Hepatitis_C